Dual MTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

被引：0
|
作者：
Garcia-Garcia, C. [1 ]
Ibrahim, Y. H. [1 ]
Serra, V. [1 ]
Calvo, M. T. [1 ]
Aura, C. [1 ]
Perez, J. [1 ]
Rommel, C. [2 ]
Tabernero, J. [1 ]
Baselga, J. [3 ]
Scaltriti, M. [3 ]
机构：
[1] Vall dHebron Inst Oncol, Barcelona, Spain
[2] Intellikine Inc, La Jolla, CA USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)71437-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
804
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [21] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
  • [22] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [23] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [24] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [25] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Elisa Van Raemdonck
    G. Floris
    P. Berteloot
    A. Laenen
    I. Vergote
    H. Wildiers
    K. Punie
    P. Neven
    Breast Cancer Research and Treatment, 2021, 185 : 183 - 194
  • [26] Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
    Kadri Altundag
    Journal of Neuro-Oncology, 2017, 135 : 639 - 639
  • [27] Her2 positive subtype and breast cancer brain metastasis: any effect of anti-Her2 targeted therapy?
    Altundag, Kadri
    JOURNAL OF NEURO-ONCOLOGY, 2017, 135 (03) : 639 - 639
  • [28] Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
    Shah, Chirayu
    Miller, Todd W.
    Wyatt, Shelby K.
    McKinley, Eliot T.
    Olivares, Maria Graciela
    Sanchez, Violeta
    Nolting, Donald D.
    Buck, Jason R.
    Zhao, Ping
    Ansari, M. Sib
    Baldwin, Ronald M.
    Gore, John C.
    Schiff, Rachel
    Arteaga, Carlos L.
    Manning, H. Charles
    CLINICAL CANCER RESEARCH, 2009, 15 (14) : 4712 - 4721
  • [29] ESAM reduces anti-HER2 therapy sensitivity by activating mTOR pathway in HER2 positive breast cancer
    Wu, Jiong
    Zhou, Xujie
    Chi, Yayun
    Xue, Jingyan
    CANCER RESEARCH, 2023, 83 (05)
  • [30] Prediction of HER2 positive breast cancer patients' response to anti-HER2 therapy using mRNA level
    Atallah, N.
    Makhlouf, S.
    Li, X. M.
    Zhangy, Y.
    Rakha, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 114 - 114
12345